Mark your calendar! Don't miss Giuliana Vallanti's presentation
Our AGC Biologics' VP of Development & Global R&D for Cell & Gene Therapies, Giuliana Vallanti, will be presenting during the event.
Don't miss her presentation "Building Flexible End-to-End Cell Therapy Manufacturing Strategies" during Session 10d: Manufacturing (BEL PARALLEL) - 8:30 on Friday, October 27. We hope to see you there!
Two of our SME's will also be presenting at poster sessions starting Wednesday, October 25 in Gare Maritime. Francesca Rossetti will be in P241 from 17:00-18:15 and Luca Crippa will be in P244 18:15-19:30.
As well as, Thursday, October 26 in Gar Maritime. Luca Crippa will be in P244 from 19:30-20:30 and Francesca Rossetti will be in P241 from 20:30-21:30.
MEET OUR TEAM
Would you like to talk with one of our team members? Interested in learning more about our global network and capabilities? Click the button below or email one of our attending representatives at the event to set up a meeting.
BravoAAV™ and ProntoLVV™ are end-to-end platforms offering a proprietary GOI backbone and plug-and-play templates for any project. Our services include proprietary plasmids, in-house analytical panels, master cell banks, pre-qualified processes and fill and finish services.
Our new templated adeno-associated viral vector platform.
AGC Biologics’ cell therapy services support every stage of the product journey, from pre-clinical through commercialization. At our Milan and Longmont facilities, we can work with virtually any cell type – including Human Mesenchymal Stem Cells (hMSCs), Exosomes, CD34+, T-Cells, NK Cells, and more.
Using the latest autologous and allogeneic methods, we help your products meet the exact specifications for patients in a clinical or commercial setting.
To support your pDNA needs, AGC Biologics utilizes a customized process based on your specific plasmid and hosting system. We have extensive technical expertise in fermentation, purification, and analytics, and our highly experienced teams routinely manufacture GMP-grade pDNA materials. This work includes starting material for gene therapy, and viral vector manufacturing.
AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). Our sites in the U.S. and Italy have supported four commercial products.
Our ready-to-use platform capabilities for AAV and LVV programs are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house.